Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system.

Sakurai Y, Hatakeyama H, Sato Y, Hyodo M, Akita H, Harashima H.

Mol Ther. 2013 Jun;21(6):1195-203. doi: 10.1038/mt.2013.57. Epub 2013 Apr 9.

2.

RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system.

Sakurai Y, Hatakeyama H, Sato Y, Hyodo M, Akita H, Ohga N, Hida K, Harashima H.

J Control Release. 2014 Jan 10;173:110-8. doi: 10.1016/j.jconrel.2013.10.003. Epub 2013 Oct 11.

PMID:
24120854
3.

A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo.

Sato Y, Hatakeyama H, Sakurai Y, Hyodo M, Akita H, Harashima H.

J Control Release. 2012 Nov 10;163(3):267-76. doi: 10.1016/j.jconrel.2012.09.009. Epub 2012 Sep 20.

PMID:
23000694
4.

[Development of an efficient short interference RNA (siRNA) delivery system with a new pH-sensitive cationic lipid].

Sato Y, Hatakeyama H, Hyodo M, Akita H, Harashima H.

Yakugaku Zasshi. 2012;132(12):1355-63. Review. Japanese.

5.

Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA.

Sakurai Y, Hatakeyama H, Sato Y, Akita H, Takayama K, Kobayashi S, Futaki S, Harashima H.

Biomaterials. 2011 Aug;32(24):5733-42. doi: 10.1016/j.biomaterials.2011.04.047. Epub 2011 May 24.

PMID:
21605898
6.

Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas.

Sakurai Y, Hatakeyama H, Akita H, Harashima H.

Mol Pharm. 2014 Aug 4;11(8):2713-9. doi: 10.1021/mp500245z. Epub 2014 May 12.

PMID:
24800640
7.

Size-dependent specific targeting and efficient gene silencing in peritoneal macrophages using a pH-sensitive cationic liposomal siRNA carrier.

Matsui H, Sato Y, Hatakeyama H, Akita H, Harashima H.

Int J Pharm. 2015 Nov 10;495(1):171-8. doi: 10.1016/j.ijpharm.2015.08.044. Epub 2015 Sep 7.

PMID:
26355712
8.

Efficient Packaging of Plasmid DNA Using a pH Sensitive Cationic Lipid for Delivery to Hepatocytes.

Sakurai Y, Matsuda T, Hada T, Harashima H.

Biol Pharm Bull. 2015;38(8):1185-91. doi: 10.1248/bpb.b15-00138.

9.

Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid.

Hatakeyama H, Akita H, Ito E, Hayashi Y, Oishi M, Nagasaki Y, Danev R, Nagayama K, Kaji N, Kikuchi H, Baba Y, Harashima H.

Biomaterials. 2011 Jun;32(18):4306-16. doi: 10.1016/j.biomaterials.2011.02.045. Epub 2011 Mar 22.

PMID:
21429576
10.

Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection.

Yamamoto N, Sato Y, Munakata T, Kakuni M, Tateno C, Sanada T, Hirata Y, Murakami S, Tanaka Y, Chayama K, Hatakeyama H, Hyodo M, Harashima H, Kohara M.

J Hepatol. 2016 Mar;64(3):547-55. doi: 10.1016/j.jhep.2015.10.014. Epub 2015 Oct 24.

11.

A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo.

Hatakeyama H, Ito E, Akita H, Oishi M, Nagasaki Y, Futaki S, Harashima H.

J Control Release. 2009 Oct 15;139(2):127-32. doi: 10.1016/j.jconrel.2009.06.008. Epub 2009 Jun 21.

PMID:
19540888
12.

Efficient short interference RNA delivery to tumor cells using a combination of octaarginine, GALA and tumor-specific, cleavable polyethylene glycol system.

Sakurai Y, Hatakeyama H, Akita H, Oishi M, Nagasaki Y, Futaki S, Harashima H.

Biol Pharm Bull. 2009 May;32(5):928-32.

13.

siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing.

Cardoso AL, Simões S, de Almeida LP, Pelisek J, Culmsee C, Wagner E, Pedroso de Lima MC.

J Gene Med. 2007 Mar;9(3):170-83.

PMID:
17351968
14.
15.

Functional improvement of an IRQ-PEG-MEND for delivering genes to the lung.

Ishitsuka T, Akita H, Harashima H.

J Control Release. 2011 Aug 25;154(1):77-83. doi: 10.1016/j.jconrel.2011.05.012. Epub 2011 May 17.

PMID:
21619903
16.

Octaarginine-modified multifunctional envelope-type nano device for siRNA.

Nakamura Y, Kogure K, Futaki S, Harashima H.

J Control Release. 2007 Jun 22;119(3):360-7. Epub 2007 Mar 23.

PMID:
17478000
17.

Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug.

Garbuzenko OB, Saad M, Betigeri S, Zhang M, Vetcher AA, Soldatenkov VA, Reimer DC, Pozharov VP, Minko T.

Pharm Res. 2009 Feb;26(2):382-94. doi: 10.1007/s11095-008-9755-4. Epub 2008 Oct 29.

PMID:
18958402
18.

siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes.

Hattori Y, Nakamura A, Arai S, Kawano K, Maitani Y, Yonemochi E.

J Liposome Res. 2015;25(4):279-86. doi: 10.3109/08982104.2014.992024. Epub 2015 Sep 4.

PMID:
25543847
19.

Mono-arginine Cholesterol-based Small Lipid Nanoparticles as a Systemic siRNA Delivery Platform for Effective Cancer Therapy.

Lee J, Saw PE, Gujrati V, Lee Y, Kim H, Kang S, Choi M, Kim JI, Jon S.

Theranostics. 2016 Jan 1;6(2):192-203. doi: 10.7150/thno.13657. eCollection 2016.

20.

Incorporation of histone derived recombinant protein for enhanced disassembly of core-membrane structured liposomal nanoparticles for efficient siRNA delivery.

Wang Y, Zhang L, Guo S, Hatefi A, Huang L.

J Control Release. 2013 Nov 28;172(1):179-89. doi: 10.1016/j.jconrel.2013.08.015. Epub 2013 Aug 23.

Supplemental Content

Support Center